AccuMedical Nets ￥100M in Series B Funding Round

According to VCBeat, recently, Beijing-based AccuMedical completed Series B financing of more than 100 million yuan, led by Sequoia Capital China, with participation from Huagai Capital. Haoyue Capital served as the exclusive financial advisor in the latest round.

Found in 2016, AccuMedical is a med-tech company focused on developing innovative medical devices for solving clinical challenges. It has currently developed a series of neurovascular devices for neurointerventional surgery. The company has an R&D center in California US and manufacturing and supporting operation center in Beijing China.

China is one of the countries with the highest incidence of stroke in the world. It has been the major cause of death for Chinese patients for 20 years, with an overall mortality rate exceeding 60%. The China Stroke Prevention Report (2018) shows that by 2030, there will be 31.77 million stroke patients nationwide.

With the support of the medical policy, the shortening surgical learning curve, and other favorable factors, the neurointerventional field will usher in a golden decade. In this fast-growing industry, with the global vision of the R&D team and in-depth understanding of the pain point in clinical applications, AccuMedical has completed the innovative design of multiple products and has access to the green channel pathway of the NMPA.

Sequoia Capital China is a VC firm focused on seed-stage, mid-stage, late-stage, and growth investments in the fintech sector.

Formed in September 2005, Sequoia Capital China has an impressive and diverse portfolio comprising about 300 dynamic companies that deliver high returns on investment using differentiated technologies and innovative business models, including Alibaba, VIPshop.com, Sina.com, Didi, JD.com, Ourpalm, Qihoo 360, Jumei, Momo, and so on.

Founded in 2012 and headquartered in Beijing, Huagai Capital is a private equity investment firm that invests in start-up or growth companies in the areas of healthcare, TMT, and culture.